期刊： ANNALS OF HEMATOLOGY, 2022; 101 (2)
Persistent thrombocytopenia (PT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of bleeding......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (10)
Relapse and refractoriness remain the major obstacles in clinical treatment of acute myeloid leukemia (AML). Efficacy of current therapeutic strategie......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
To investigate the pathogenesis and the refractory/relapse mechanisms in patients with t(16;21)(p11;q22), we retrospectively analyzed the clinical dat......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
Hetrombopag is the only CFDA-approved thrombopoietin (TPO) receptor agonist for severe aplastic anemia (SAA) in China. Its chemical structure has an i......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (4)
Idarubicin 12 mg/m(2) has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of id......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (5)
Immune thrombocytopenia (ITP) is the most common clinical bleeding disorder with a high mortality rate and poor long-term survival quality in severe p......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (8)
Background Malignant lymphomas are one of the most common cancers worldwide and with high biologic heterogeneity, while the phosphoinositide 3 kinase ......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (3)
We started a single-arm, phase II, open-label, prospective clinical trial using steroids-ruxolitinib as the first-line therapy for intermediate- to hi......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (3)
HBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (9)
The present study aims to evaluate the characteristics and treatment outcomes of adult Langerhans cell histiocytosis (LCH) patients with thyroid invol......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (4)
Acquired aplastic anemia (AA) is an autoimmune disease characterized by hematopoietic stem and progenitor cell destruction in bone marrow. The non-cla......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (10)
Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential opt......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (10)
P53 prognostic cut-off values differ between studies of mantle cell lymphoma (MCL), and its immunohistochemistry (IHC) interpretation is still based o......
